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Efficacy and safety of biosimilar CT-P17
versus reference adalimumab in subjects
with rheumatoid arthritis: 24-week results
from a randomized study
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Slawomir Jeka7, Agnieszka Zielinska8, Jakub Trefler9, Katarzyna Bartnicka-Maslowska10,
Magdalena Krajewska-Wlodarczyk11, Piotr A. Klimiuk12, Sang Joon Lee13, Yun Ju Bae13, Go Eun Yang13,
Jae Kyoung Yoo13, Daniel E. Furst14,15,16† and Edward Keystone17*†
Abstract
Background: To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free
adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active
rheumatoid arthritis (RA).
Methods: This randomized, double-blind phase III study (ClinicalTrials.gov, NCT03789292) randomized (1:1) subjects
with active RA at 52 centers to receive CT-P17 or EU-adalimumab 40 mg subcutaneously every 2 weeks until week
52. Results to week 24 are reported here. The primary endpoint was 20% improvement by American College of
Rheumatology criteria (ACR20) response rate at week 24. Equivalence was concluded if the corresponding
confidence intervals (CIs) for the estimate of treatment difference were within predefined equivalence margins: − 15
to 15% (95% CI; European Medicines Agency assumption); − 12 to 15% (90% CI; Food and Drug Administration
assumption). Additional efficacy, pharmacokinetic, usability, safety, and immunogenicity endpoints were evaluated.
Results: 648 subjects were randomized (324 CT-P17; 324 EU-adalimumab). The ACR20 response rate at week
24 was 82.7% (n = 268/324) in both groups (intention-to-treat population). The 95% CI (− 5.94 to 5.94) and
90% CI (− 4.98 to 4.98) were within predefined equivalence margins for both assumptions and equivalent
efficacy was concluded. Additional endpoints and overall safety were comparable between groups. Mean
trough serum concentrations of CT-P17 were slightly higher than those of EU-adalimumab. Immunogenicity
was slightly lower numerically for the CT-P17 group than for the EU-adalimumab group.
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Conclusions: CT-P17 and EU-adalimumab have equivalent efficacy and comparable safety and
immunogenicity in subjects with active RA. Overall safety of CT-P17 is consistent with the known safety
profile of reference adalimumab.
Trial registration: ClinicalTrials.gov, NCT03789292. Registered 28 December 2018—retrospectively registered.
Keywords: Adalimumab, Biologics, Biosimilars, Comparative effectiveness, Immunogenicity, Monoclonal
antibodies, Rheumatoid arthritis, Safety, Tumor necrosis factor inhibitors
Background
Biological disease-modifying antirheumatic drugs
(bDMARDs), such as tumor necrosis factor (TNF) inhib-
itors, are recommended for the treatment of rheumatoid
arthritis (RA) when disease activity remains moderate or
high despite conventional synthetic DMARD
(csDMARD) monotherapy [1]. Adalimumab is an anti-
TNF monoclonal antibody that effectively treats RA [2–
5]. Biosimilars are highly similar to their reference prod-
ucts in terms of quality characteristics, biological activ-
ity, safety, and efficacy [6]. Since 2016, several
adalimumab biosimilars have been licensed by the US
Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) [7, 8]. European League
Against Rheumatism (EULAR) recommendations for the
treatment of RA position biosimilar DMARDs
(bsDMARDs) equivalently to their reference products in
treatment algorithms, and suggest that lower-priced bio-
similars are preferred for their potential to reduce
healthcare expenditures [9].
CT-P17 is in development as a proposed adalimumab
biosimilar [10, 11]. CT-P17 is administered at 100mg/ml,
reflecting the high-concentration formulation of reference
adalimumab [12–14], and is also citrate-free, which could
reduce discomfort during injection [12, 15]. To date, CT-
P17 has been evaluated in two randomized phase I studies
evaluating the pharmacokinetics (PK) and safety of CT-
P17 in healthy adults: a double-blind study comparing
CT-P17 to European Union-approved adalimumab (EU-
adalimumab) and US-licensed adalimumab (ClinicalTrials.
gov NCT03970824) [11] and an open-label study compar-
ing CT-P17 administration via autoinjector or prefilled
syringe (ClinicalTrials.gov NCT04295356) [16].
This randomized, active-controlled, double-blind, mul-
ticenter, phase III study was designed to demonstrate
that the efficacy of CT-P17 at week 24 is equivalent to
that of EU-adalimumab. The study also evaluated PK,
usability, and overall safety, including immunogenicity.
Methods
Study design and procedures
This randomized, double-blind, active-controlled, multi-
center, phase III study was conducted at 52 centers in
six countries (Bulgaria, Hungary, Lithuania, Peru,
Poland, Ukraine; see Supplementary Table 1, Add-
itional file 1). There were three study periods: screening
(days − 42 to − 1), treatment (weeks 0–48), and end-of-
study (week 52). Before dosing at week 0, subjects were
randomized (1:1) to receive treatment with 40 mg (100
mg/ml) of either CT-P17 or EU-adalimumab (Humira,
AbbVie Deutschland GmbH Co. KG, Ludwigshafen,
Germany) every 2 weeks (q2w) until week 24 (treatment
period 1). Before dosing at week 26, subjects in the EU-
adalimumab group were randomized (1:1) either to con-
tinue EU-adalimumab or to switch to CT-P17 (both q2w
until week 48) (treatment period 2). Subjects receiving
CT-P17 during treatment period 1 continued to receive
CT-P17 in treatment period 2. Results up to week 24 are
reported here.
CT-P17 and EU-adalimumab were administered by
subcutaneous injection via prefilled syringe. After
training in proper injection technique, subjects (or
caregivers, as needed) could self-administer injections
at home, unless injection at the study center was re-
quired for usability assessment. Subjects also received
treatment with methotrexate (MTX; 12.5–25 mg/week,
or 10 mg/week if intolerant to a higher dose, oral or
parenteral [intramuscular or subcutaneous] dose) and
folic acid (≥ 5 mg/week, oral).
Randomization was conducted using an interactive
web response system (IWRS). The biostatistics team
used Rave Randomization and Trial Supply Manage-
ment (Medidata Solutions, New York) to generate the
randomization schedule for the IWRS, which linked
sequential subject randomization numbers to treat-
ment codes. Randomization was by permuted block
(block size remains blinded until final database lock)
and was stratified by country and Simplified Disease
Activity Index (SDAI) at screening (> 26 vs ≤ 26). As
prespecified in the protocol, the study was unblinded
for reporting purposes after the database lock for data
up to week 24. Efficacy, PK, usability, immunogen-
icity, and safety endpoints were evaluated by separate,
predefined unblinded teams constituted by the spon-
sor and by the Contract Research Organization
(CRO). The investigators, subjects, and other teams in
the CRO and the sponsor will remain blinded until
the end of the study.
Kay et al. Arthritis Research & Therapy           (2021) 23:51 Page 2 of 12
The study was performed in accordance with the Dec-
laration of Helsinki [17] and Good Clinical Practice
guidelines [18]. All national, state, and local laws or reg-
ulations were followed. Before study initiation, the study
protocol was reviewed and approved by the independent
ethics committee/institutional review board at each site
(see Supplementary Table 1, Additional file 1). All sub-
jects provided written informed consent. The study was
registered with ClinicalTrials.gov (NCT03789292).
Subjects
Full eligibility criteria are detailed in Additional file 1.
Subjects ranged between 18 and 75 years of age, were di-
agnosed with RA according to the 2010 American Col-
lege of Rheumatology (ACR)/EULAR classification
criteria [19], and had active disease, defined by the pres-
ence of ≥ 6 swollen joints (of 66 assessed), ≥ 6 tender
joints (of 68 assessed), and either erythrocyte sedimenta-
tion rate (ESR) > 28 mm/hour or serum C-reactive pro-
tein (CRP) concentration > 1.0 mg/dl (> 10 mg/l) at
screening. Subjects had received oral or parenteral MTX
at a dose of 12.5–25 mg/week, or 10 mg/week if intoler-
ant to a higher dose, for ≥ 12 weeks, and had been on a
stable dose and route of administration of MTX for ≥ 4
weeks before the first administration of study drug (day
1). Key exclusion criteria included prior bDMARD or
targeted synthetic DMARD treatment for RA or prior
TNF inhibitor treatment for any diagnosis; active or la-
tent tuberculosis, or history of tuberculosis; or history of
or current serious infection.
Study endpoints
The primary efficacy endpoint was the proportion of
subjects achieving clinical response according to 20%
improvement by ACR response criteria (ACR20) at week
24. Secondary efficacy endpoints up to week 24 were
ACR20, ACR50, and ACR70 response, hybrid ACR re-
sponse, Disease Activity Score in 28 joints (DAS28)-CRP
response, EULAR (CRP) response, SDAI and Clinical
Disease Activity Index (CDAI) remission rate, and 36-
item Short Form Health Survey (SF-36) physical and
mental component scores. DAS28-CRP and Boolean re-
mission rates were analyzed post hoc. Trough serum
adalimumab concentration (Ctrough) was evaluated as a
secondary PK endpoint. Usability evaluations (Bulgaria
and Poland only) included subject-reported outcomes
from the Self-Injection Assessment Questionnaire
(SIAQ) administered before (PRE-SIAQ) and after
(POST-SIAQ) self-injection, and successful self-injection
as determined by Self-Injection Assessment Checklist
completed by study center staff. Safety was evaluated
throughout; immunogenicity and local site pain were
also assessed.
Study assessments
Study assessments and time points for evaluation are
specified in Supplementary Table 2 (Additional file 1).
For efficacy assessments, procedures were performed at
the study center before study drug administration. A
blinded independent joint assessor was assigned at each
study center. Blood samples for PK analysis were ob-
tained predose (immediately before study drug injection)
for all PK sampling time points. Usability assessments
were conducted at weeks 4, 6, 8, and 24. Safety assess-
ments performed throughout included treatment-
emergent adverse events (TEAEs), TEAEs of special
interest (TEAESI), immunogenicity, clinical monitoring
for tuberculosis, and review of prior and concomitant
medications. TEAEs were recorded according to the
Common Terminology Criteria for Adverse Events v5.0
and were coded to System Organ Class (SOC) and Pre-
ferred Term according to the Medical Dictionary for
Regulatory Affairs v22.0. Prior and concomitant medica-
tions were coded using the World Health Organization
Drug Dictionary (March 2019 version). Protocol-
specified TEAESIs were injection-site reactions (ISRs),
hypersensitivity/allergic reactions, infections, and malig-
nancies. Local site pain was assessed by using a 100-mm
visual analog scale (VAS) at all study visits (except weeks
12 and 20).
Immunogenicity was evaluated at all study visits. Anti-
drug antibodies (ADAs) were detected using a validated
electrochemiluminescent bridging assay with acid dis-
sociation. ADA-positive samples underwent further ana-
lysis to confirm the specificity of binding and to quantify
ADA titer. If a sample was confirmed positive for spe-
cific ADAs, the presence of neutralizing antibodies
(NAbs) was investigated. A validated electrochemilumi-
nescent assay with affinity capture elution was used to
measure neutralizing activity against adalimumab in hu-
man serum.
Statistical analyses
A sample size of 450 subjects (225 per treatment group)
was determined to provide ≥ 80% statistical power to
demonstrate equivalence of ACR20 response at week 24,
using nQuery Adviser (v7.0; nQuery, Boston, MA). This
calculation was based on two sets of statistical assump-
tions to meet the different requirements of regulatory
authorities in the European Union and the USA: an
equivalence margin of − 15 to 15% using a 2 1-sided
2.5% significance level of an equivalence test (predefined
in the protocol; EMA assumption), and an asymmetric
equivalence margin of − 12 to 15% using a 2 1-sided 5%
significance level of an equivalence test (FDA assump-
tion). To allow for a possible dropout rate of 20%, the
target sample size was 564 subjects (282 per treatment
group).
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Analysis populations are described in Additional file 1.
The intention-to-treat (ITT) population included all
subjects enrolled and randomized to receive a dose of ei-
ther study drug, regardless of whether study drug dosing
was completed. The ITT population was the primary
analysis population for the primary endpoint, which was
also assessed in the per-protocol (PP) population as a
supportive analysis. The analysis was conducted by the
exact binomial approach using a Farrington-Manning
score method (inverting 2 1-sided test) [20]. A sensitivity
analysis for the primary efficacy endpoint was performed
in both the ITT and the PP populations using logistic re-
gression with treatment group as a fixed effect and
country and disease activity by SDAI at screening as co-
variates. Selected analyses were also conducted by ADA
status. Post hoc analyses were conducted to compare
parameters between treatment groups (Tables 1, 2, and
3), with p values generated by the Wald test (for propor-
tional values) or t test (for mean values). All statistical
analyses were performed using SAS software v9.4 (SAS
Institute, Cary, NC).
Results
Subject disposition and baseline characteristics
Subjects were recruited between December 5, 2018, and
April 25, 2019 (last subject week 24 visit: October 8,
2019). Of the 648 subjects who were randomized, 324 to
each of the CT-P17 and EU-adalimumab groups (Fig. 1),
612 (94.4%) completed study treatment up to week 24
(CT-P17, 305/324 [94.1%]; EU-adalimumab, 307/324
[94.8%]). Nineteen (5.9%) and 17 (5.2%) subjects discon-
tinued study treatment in the CT-P17 and EU-
Table 1 Demographics and baseline disease characteristics (ITT population, unless otherwise specified)
CT-P17 (N = 324) EU-adalimumab (N = 324)
Age (years), median (range) 53.5 (18–75) 54.0 (19–75)
Sex, n (%)
Male 75 (23.1) 59 (18.2)
Female 249 (76.9) 265 (81.8)
Race, n (%)
White 299 (92.3) 298 (92.0)
Mestizo 24 (7.4) 26 (8.0)
Native Peruvian 1 (0.3) 0
Ethnicity, n (%)
Hispanic or Latino 29 (9.0) 34 (10.5)
Non-Hispanic or non-Latino 295 (91.0) 290 (89.5)
RA disease duration (years), mean (SD) 6.79 (6.76) 6.59 (6.81)
SDAI at screening, n (%)
SDAI ≤ 26 30 (9.3) 34 (10.5)
SDAI > 26 294 (90.7) 290 (89.5)
SDAI, mean (SD) 40.0 (11.5) 39.8 (11.1)
CDAI, mean (SD) 39.0 (11.0) 38.7 (10.8)
DAS28-CRP, mean (SD) 5.538 (0.8738) 5.547 (0.8525)
Tender joint count, mean (SD) 20.5 (10.2) 20.1 (10.1)
Swollen joint count, mean (SD) 14.0 (6.33) 14.0 (6.46)
Subject’s assessment of pain, mean (SD)a 69.7 (18.7) 70.0 (16.2)
Subject’s global assessment of disease activity, mean (SD)a 69.8 (17.8) 69.6 (16.3)
Physician’s global assessment of disease activity, mean (SD)a 67.5 (14.7) 67.0 (15.5)
HAQ estimate of physical ability, mean (SD) 1.41 (0.59) 1.48 (0.56)
CRP (mg/dl), mean (SD) 0.975 (1.60) 1.10 (1.91)
ESR (mm/h), mean (SD) 42.3 (15.98) 42.9 (16.94)
Note: There were no significant differences between the CT-P17 and EU-adalimumab groups for any parameter (p > 0.05). For age (years), mean (SD) values were
used for the statistical analysis
aAssessed by 100-mm visual analog scale
Anti-CCP anti-cyclic citrullinated peptide, CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte
sedimentation rate, EU-adalimumab European Union-approved adalimumab, HAQ Health Assessment Questionnaire, ITT intention-to-treat, RA rheumatoid arthritis,
RF rheumatoid factor, SD standard deviation, SDAI Simplified Disease Activity Index
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adalimumab groups, respectively. Withdrawal by subject
was the most frequent reason for discontinuation (CT-
P17, 9 [2.8%] subjects; EU-adalimumab, 7 [2.2%] sub-
jects), followed by TEAEs (CT-P17, 6 [1.9%]; EU-
adalimumab, 7 [2.2%]). Of the 36 (5.6%) subjects who
discontinued study treatment, 25 (3.9%) terminated the
study (CT-P17, 15 [4.6%]; EU-adalimumab, 10 [3.1%])
and 11 (1.7%) (CT-P17, 4 [1.2%]; EU-adalimumab, 7
[2.2%]) continued participation in the study.
Baseline demographics and disease characteristics were
balanced between treatment groups (Table 1). Median
age was 53.5 and 54.0 years for CT-P17 and EU-
adalimumab, respectively. Most subjects were female
(CT-P17, 76.9%; EU-adalimumab, 81.8%) and were mainly
enrolled by sites in Eastern European countries, par-
ticularly Poland (231 [71.3%] subjects for both
groups). Most subjects had high disease activity (SDAI
score > 26). Stratification factors, SDAI score category,
and country were well balanced between groups.
Efficacy
Primary efficacy analysis
The ACR20 response rate at week 24 (Fig. 2a) was 82.7%
(n = 268/324) for both the CT-P17 and EU-adalimumab
Table 2 EULAR (CRP) response rate and SDAI, CDAI, DAS28






EULAR (CRP) response, n (%)
Week 2
Good response 22 (6.8) 13 (4.0)
Moderate
response
154 (47.5) 139 (42.9)
Week 4
Good response 72 (22.2) 68 (21.0)
Moderate
response
162 (50.0) 167 (51.5)
Week 8
Good response 133 (41.0) 123 (38.0)
Moderate
response
143 (44.1) 144 (44.4)
Week 12
Good response 162 (50.0) 165 (50.9)
Moderate
response
131 (40.4) 124 (38.3)
Week 16
Good response 181 (55.9) 174 (53.7)
Moderate
response
112 (34.6) 109 (33.6)
Week 20
Good response 202 (62.3) 201 (62.0)
Moderate
response
91 (28.1) 87 (26.9)
Week 24
Good response 208 (64.2) 208 (64.2)
Moderate
response
86 (26.5) 81 (25.0)
CDAI remission rate, n (%)
Week 2 2 (0.6) 2 (0.6)
Week 4 11 (3.4) 11 (3.4)
Week 8 21 (6.5) 24 (7.4)
Week 12 47 (14.5) 42 (13.0)
Week 16 51 (15.7) 63 (19.4)
Week 20 69 (21.3) 85 (26.2)
Week 24 82 (25.3) 86 (26.5)
SDAI remission rate, n (%)
Week 2 2 (0.6) 2 (0.6)
Week 4 12 (3.7) 12 (3.7)
Week 8 22 (6.8) 22 (6.8)
Week 12 47 (14.5) 44 (13.6)
Week 16 53 (16.4) 65 (20.1)
Week 20 69 (21.3) 87 (26.9)
Table 2 EULAR (CRP) response rate and SDAI, CDAI, DAS28






Week 24 86 (26.5) 93 (28.7)
DAS28 (CRP) remission rate, n (%)
Week 2 11 (3.4) 10 (3.1)
Week 4 32 (9.9) 38 (11.7)
Week 8 67 (20.7) 68 (21.0)
Week 12 109 (33.6) 107 (33.0)
Week 16 128 (39.5) 118 (36.4)
Week 20 150 (46.3) 146 (45.1)
Week 24 158 (48.8) 157 (48.5)
Boolean remission rate, n (%)
Week 2 2 (0.6) 2 (0.6)
Week 4 9 (2.8) 10 (3.1)
Week 8 17 (5.2) 17 (5.2)
Week 12 32 (9.9) 33 (10.2)
Week 16 40 (12.3) 56 (17.3)
Week 20 56 (17.3) 66 (20.4)
Week 24 58 (17.9) 68 (21.0)
Note: There were no significant differences between the CT-P17 and EU-
adalimumab groups for any parameter (p > 0.05)
CDAI Clinical Disease Activity Index, CRP C-reactive protein, DAS28 Disease
Activity Score in 28 joints, EU-adalimumab European Union-approved
adalimumab, EULAR European League Against Rheumatism, SDAI Simplified
Disease Activity Index
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groups (ITT population). The 95% confidence interval
(CI) of − 5.94 to 5.94 for the estimate of treatment dif-
ference was entirely within the predefined equivalence
margin of − 15 to 15% (EMA assumption), demonstrat-
ing therapeutic equivalence between treatment groups.
Results for the PP population supported those for the
ITT population (CT-P17, 87.0% [n = 248/285]; EU-
adalimumab, 87.0% [n = 240/276]), with the 95% CI of
− 5.60 to 5.78 for the estimate of treatment difference.
Likewise, for both analysis populations, 90% CIs for the
estimate of treatment difference (− 4.98 to 4.98 in the
ITT population and − 4.70 to 4.86 in the PP population)
were entirely within the asymmetric equivalence margin
of − 12 to 15% (FDA assumption), thereby also demon-
strating therapeutic equivalence between treatment
groups. Sensitivity analysis using logistic regression with
covariates for the primary endpoint provided similar
results, − 5.75 to 5.86 (ITT population) and − 5.07 to 5.93
(PP population) for 95% CI.
Secondary and additional efficacy analyses
The proportions of subjects achieving ACR20, ACR50,
and ACR70 responses up to week 24 were similar be-
tween the CT-P17 and EU-adalimumab groups (Fig. 2a,
b; Supplementary Table 3, Additional file 1). Mean
values of and change from baseline in DAS28-CRP (Fig.
2c), CDAI (Fig. 2d), and SDAI (Fig. 2e) were comparable
between groups up to week 24, as were EULAR (CRP)
response rates and SDAI, CDAI, DAS28 (CRP), and
Boolean remission rates (Table 2). Mean hybrid ACR
scores increased from week 2 to week 24 and were
similar between groups (Supplementary Table 3, Add-
itional file 1). Mean SF-36 physical and mental compo-
nent scores increased from baseline to week 24; mean
increases up to week 24 were similar between groups. At
week 24, mean (SD) change from baseline in the SF-36
physical component score was 7.869 (7.4184) for CT-
P17 (n = 309) and 8.213 (8.0179) for EU-adalimumab
(n = 312). At week 24, mean (SD) change from baseline
in the SF-36 mental component score was 5.879 (9.8480)
for CT-P17 (n = 309) and 6.585 (9.7404) for EU-
adalimumab (n = 312).
Pharmacokinetic analysis
The mean adalimumab Ctrough was comparable between
groups in the PK population, although values were slightly
higher in the CT-P17 than in the EU-adalimumab group
(Supplementary Table 4, Additional file 1). Mean Ctrough
increased gradually from baseline to week 22 for both
groups (Supplementary Figure 1, Additional file 1).
Usability analysis
Mean scores for each domain of the PRE-SIAQ and
POST-SIAQ were comparable between treatment groups
(Supplementary Table 5, Additional file 1). All subjects
in the population in which usability was assessed com-
pleted self-injection successfully.
Safety
Overall, the proportion of subjects experiencing ≥ 1
TEAE was similar between treatment groups (CT-P17,
169 [52.2%] subjects; EU-adalimumab, 184 [56.8%]
Table 3 Treatment-emergent adverse events (safety population)
CT-P17 (N = 324) EU-adalimumab (N = 324)
Subjects with ≥ 1 TEAE, n (%) 169 (52.2) 184 (56.8)
Study drug-related 88 (27.2) 99 (30.6)
TEAEs reported in ≥ 5% of subjects in either treatment group
ISR 16 (4.9) 22 (6.8)
Nasopharyngitis 17 (5.2) 20 (6.2)
Upper respiratory tract infection 17 (5.2) 20 (6.2)
Neutropenia 14 (4.3) 17 (5.2)
Subjects with ≥ 1 TESAE, n (%) 10 (3.1) 16 (4.9)
Subjects with ≥ 1 TEAE leading to study drug discontinuation, n (%) 5 (1.5) 8 (2.5)
Subjects with ≥ 1 TEAE classified as hypersensitivity/allergic reactions, n (%) 2 (0.6) 4 (1.2)
Subjects with ≥ 1 TEAE classified as ISR, n (%) 16 (4.9) 22 (6.8)
Subjects with ≥ 1 TEAE classified as infection, n (%) 97 (29.9) 103 (31.8)
Subjects with ≥ 1 TEAE classified as malignancy, n (%) 1 (0.3)a 0
Total number of TEAEs leading to death 0 0
Note: There were no significant differences between the CT-P17 and EU-adalimumab groups for any parameter (p > 0.05)
aBreast cancer that was considered unrelated to study drug; the subject’s family history of breast cancer was considered a risk factor by the investigator
TEAE treatment-emergent adverse event, EU-adalimumab European Union-approved adalimumab, ISR injection-site reaction, TESAE treatment-emergent serious
adverse event
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subjects) (Table 3). Most TEAEs were grade 1 or 2 in in-
tensity. TEAEs considered by the investigator to be study
drug-related were reported by 187 (28.9%) subjects, with
similar proportions between treatment groups (CT-P17,
88 [27.2%]; EU-adalimumab, 99 [30.6%]) (Table 3). A
similar proportion of subjects in each group experienced
TEAEs leading to study drug discontinuation; of these, 2
(0.6%) and 4 (1.2%) subjects, respectively, experienced
TEAEs that were considered study drug related. The
most frequently reported TEAEs in the CT-P17 group
were nasopharyngitis and upper respiratory tract infec-
tion (17 [5.2%] subjects each) and ISR (16 [4.9%]); in the
EU-adalimumab group, these were ISR (22 [6.8%]) and
nasopharyngitis and upper respiratory tract infection (20
[6.2%] each) (Table 3). Treatment-emergent serious
adverse events (TESAEs) were reported for 10 (3.1%)
subjects in the CT-P17 group and 16 (4.9%) in the EU-
adalimumab group (Table 3). Study drug-related TESA
Es were reported for 9 subjects overall (CT-P17, 5
[1.5%]; EU-adalimumab, 4 [1.2%]) (Supplementary
Table 6, Additional file 1). No deaths were reported up
to week 24.
TEAEs classified as hypersensitivity/allergic reactions,
ISRs, or infections were experienced by similar propor-
tions of subjects in each group (Table 3). Conversion to
positive interferon-γ release assay, up to week 24, was
experienced by 12 (3.7%) and 17 (5.2%) subjects in the
CT-P17 and EU-adalimumab groups, respectively. Latent
tuberculosis was reported in 12 (3.7%) and 15 (4.6%)
subjects in the CT-P17 and EU-adalimumab groups, re-
spectively; for 7 (2.2%) and 10 (3.1%) of these subjects,
this was considered study drug-related. All these subjects
began tuberculosis prophylaxis, except for the single
subject in each group who terminated study participa-
tion. Two (0.6%) subjects in the EU-adalimumab group
reported active tuberculosis and discontinued study
treatment. One (0.3%) subject experienced a TEAE clas-
sified as malignancy (breast cancer) in the CT-P17 group
(Table 3); however, the site investigator considered this
event to be unrelated to study drug.
Fig. 1 Subject disposition (ITT population). aSubject discontinued CT-P17 treatment due to significant dose delay due to adverse event. bTwo
subjects discontinued EU-adalimumab treatment due to subject decision due to adverse event. EU-adalimumab, European Union-approved
adalimumab; ITT, intention-to-treat
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Small imbalances were identified in the proportions of
subjects reporting TEAEs classified in the SOC of
gastrointestinal disorders (CT-P17, 24 [7.4%] subjects;
EU-adalimumab, 16 [4.9%] subjects), nervous system dis-
orders (CT-P17, 19 [5.9%] subjects; EU-adalimumab, 9
[2.8%] subjects), and metabolism and nutrition disorders
(CT-P17, 12 [3.7%] subjects; EU-adalimumab, 6 [1.9%]
subjects) (Supplementary Table 7, Additional file 1).
However, among these SOCs, other than for two grade 3
TEAEs that were considered unrelated to study drug in
the EU-adalimumab group (1 nervous system disorder of
carotid arteriosclerosis, and 1 metabolism and nutrition
disorder of hypertriglyceridemia), all TEAEs were grade
1–2 in intensity.
Mean (SD) 100-mm VAS scores for local site pain
measurements decreased over time. Results at each visit
were comparable between treatment groups. At week 0,
mean (SD) VAS scores for local site pain were 6.64
Fig. 2 Secondary efficacy endpoints up to week 24 (ITT population). ACR20 response rate up to week 24 (a). ACR20, ACR50, and ACR70 response
rates at week 24 (b). Mean change from baseline in DAS28-CRP up to week 24 (c). Mean change from baseline in CDAI value up to week 24 (d).
Mean change from baseline in SDAI value up to week 24 (e). ACR, American College of Rheumatology; ACR20, 20% improvement according to
American College of Rheumatology criteria; ACR50, 50% improvement according to American College of Rheumatology criteria; ACR70, 70%
improvement according to American College of Rheumatology criteria; CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score in
28 joints C-reactive protein; EU-adalimumab, European Union-approved adalimumab; ITT, intention-to-treat; SDAI, Simplified Disease Activity Index
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(10.887) for CT-P17 and 4.85 (7.300) for EU-
adalimumab, while mean VAS scores at week 24 had de-
creased to 4.45 (8.393) for CT-P17 and to 4.32 (8.651)
for EU-adalimumab.
Immunogenicity
At baseline, 11 (3.4%) and 6 (1.9%) subjects were ADA-
positive and 4 (1.2%) and 1 (0.3%) subjects were NAb-
positive in the CT-P17 and EU-adalimumab groups, re-
spectively (Supplementary Table 8, Additional file 1). At
week 24, 93 (28.7%) and 116 (35.8%) subjects were
ADA-positive and 83 (25.6%) and 103 (31.8%) subjects
were NAb-positive in the CT-P17 and EU-adalimumab
groups, respectively. Overall, immunogenicity was
slightly lower numerically for the CT-P17 group than for
the EU-adalimumab group throughout the study.
ADA subgroup analysis
The proportions of subjects achieving an ACR20 re-
sponse at week 24 were similar between the CT-P17 and
the EU-adalimumab treatment groups in both the ADA-
positive and ADA-negative subgroups (Supplementary
Table 9, Additional file 1). Mean Ctrough was lower in
the ADA-positive subgroup than in the ADA-negative
subgroup for both treatment groups (Supplementary
Figure 1 and Supplementary Table 4, Additional file 1).
A lower proportion of subjects in the ADA-negative sub-
group experienced ≥1 TEAE than did those in the ADA-
positive subgroup (49.7% and 59.8%, respectively); how-
ever, with a limited number of events, there was no ap-
parent correlation between the presence of ADA and the
incidence of TESAEs, TEAEs classified as hypersensitiv-
ity/reactions, or TEAEs classified as ISRs (Supplemen-
tary Table 10, Additional file 1).
Discussion
This study demonstrated equivalent efficacy of CT-P17
to EU-adalimumab in the proportion of subjects achiev-
ing an ACR20 response at week 24. This primary end-
point was met in both the ITT and PP analysis
populations for both the EMA (− 15 to 15%, 95% CI)
and the FDA (− 12 to 15%, 90% CI) statistical assump-
tions. Comparable efficacy of CT-P17 and EU-
adalimumab was demonstrated for secondary endpoints
up to week 24. PK parameters were also comparable be-
tween groups, although mean Ctrough was slightly higher
for CT-P17 than for EU-adalimumab. The usability of
CT-P17, assessed by ability to complete successful self-
injections and subject-reported outcomes, was compar-
able to that of EU-adalimumab. The overall safety profile
of CT-P17 was similar to that of EU-adalimumab, al-
though there were small imbalances between the CT-
P17 and EU-adalimumab groups for some SOCs.
In our study, the ACR20 response rate at week 24,
using high-concentration (100mg/ml) formulations of
CT-P17 and EU-adalimumab, was 82.7% in both treat-
ment groups (ITT population). These observed ACR20
response rates are only slightly above the range of
ACR20 responses for reference adalimumab (50 mg/ml)
and adalimumab biosimilars in other adalimumab biosi-
milar studies, in which ACR20 response rates at week 24
or week 26 ranged between 63.9 and 82.5% (Supplemen-
tary Figure 2, Additional file 1) [21–25]. However, our
study did not compare the high-concentration formula-
tion to the low-concentration formulation of
adalimumab.
We also investigated the influence of immunogenicity
status on the proportion of subjects achieving an ACR20
response at week 24. Overall, a slightly lower proportion
of ADA-positive subjects achieved an ACR20 response
at week 24 than did ADA-negative subjects (81.4% vs
85.1%), consistent with previous reports for reference
adalimumab and adalimumab biosimilars [13, 26]. How-
ever, within subject subgroups by ADA status, ACR20
response rates were similar between CT-P17 and EU-
adalimumab treatment groups, in line with similar data
reported previously for adalimumab biosimilars [26, 27].
In this study, we observed slightly higher mean Ctrough
values in the CT-P17 group compared with the EU-
adalimumab group. In a separate study, ADA formation
was associated with increased clearance and lower serum
adalimumab concentrations [13]. However, in this study,
AUC and clearance were not evaluated, so this could not
be examined directly. It is possible that the differences
may be associated with the lower proportion of ADA-
positive subjects in the CT-P17 versus EU-adalimumab
group. Indeed, in our study, Ctrough was generally lower
in the ADA-positive than in the ADA-negative
subgroup; Ctrough values became more similar between
groups when compared within these subgroups.
Nevertheless, Ctrough values of the ADA-positive
subgroup were within the therapeutic level of adalimu-
mab (5 to 8 μg/ml) [13]. In addition, our findings are in
keeping with previous reports for adalimumab biosimilars
[26, 28].
The overall safety profile of CT-P17 in this study was
consistent with the known safety profile of reference
adalimumab [13]. In both treatment groups, the most
frequently reported study drug-related TEAEs were ISRs,
consistent with information provided in the EU-
adalimumab summary of product characteristics [13].
ISRs, as well as the other protocol-specified TEAESIs of
hypersensitivity/allergic reactions and infections, were
experienced by similar proportions of subjects in each
treatment group. There were small imbalances, at the
SOC level, in the proportions of subjects reporting
TEAEs for gastrointestinal disorders, nervous system
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disorders, and metabolism and nutrition disorders.
These TEAEs were mostly grade 1–2 in intensity and, at
the Preferred Term level, absolute differences between
groups in the number of subjects experiencing a given
TEAE were small. When analyzed by ADA status, the
incidence of TEAEs, but not of TESAEs, was higher for
ADA-positive than for ADA-negative subjects; there was
no apparent correlation between the presence of ADAs
and hypersensitivity/allergic reactions or ISRs.
This is the first report of a phase III clinical trial com-
paring CT-P17 to reference adalimumab. Strengths of
this study include its randomized, double-blind design,
and the use of well-established outcome measures.
Equivalent efficacy of CT-P17 and EU-adalimumab was
established using both symmetric and asymmetric
equivalence margins, as agreed to by the EMA and the
FDA, respectively. In addition to the data reported from
comparing these treatments up to week 24, this study
will provide valuable information regarding the efficacy
and safety of transitioning from EU-adalimumab to CT-
P17 (during treatment period 2).
Limitations of this study include the relatively short
follow-up period (24 weeks) reported herein; however,
this study is ongoing and efficacy and safety data up to
week 52 will be reported. Although sufficient testing was
done for regulatory purposes, comprehensive PK data
were not collected. While treatment groups were well
balanced by stratification factors including country, sub-
jects from Eastern European countries, particularly
Poland, accounted for most of the study population. The
races of subjects enrolled in this study included white,
mestizo, and Native Peruvian. This could limit the global
generalizability of the findings; however, this should be
viewed in the context of the global scope of the CT-P17
clinical development program that included American
Indian or Alaska Native, Black or African American, and
Asian subjects, among which there were no differences
in clinical responses [11, 16, 29]. Also, since this was a
comparative study to demonstrate equivalence of CT-
P17 to EU-adalimumab, it did not aim to evaluate the
drugs across other ethnic groups.
The original reference adalimumab was developed as a
low-concentration (50 mg/ml) formulation containing
citrate. Subsequently, a high-concentration (100 mg/ml),
citrate-free formulation of reference adalimumab has
been developed [13, 14]. While the high-concentration
CT-P17 formulation is similar to the newer formulation
of reference adalimumab [13, 14], it differs from the
low-concentration (50 mg/ml) adalimumab biosimilars
that are currently approved [12, 30–33]. The high-
concentration formulations of both CT-P17 and refer-
ence adalimumab offer the potential to administer high-
dose (80 mg/0.8 ml) induction treatment to patients with
inflammatory bowel disease with a reduced number of
injections. In addition, the citrate-free buffer may benefit
patients by reducing discomfort during injection [12,
15].
Conclusions
In conclusion, demonstration of equivalent efficacy and
comparable safety and immunogenicity of CT-P17 to
EU-adalimumab in this study support the ongoing clin-
ical evaluation of CT-P17 as an adalimumab biosimilar.
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